drugset
drugset / Trial / NCT04689152

Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis

NCT04689152 ↗

Phase 3 Recruiting 200 enrolled Pharmicell Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This phase III clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected hepatic artery.

Timeline

Start
2021-03-02
Primary completion
2027-08-02
Completion
2028-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cellgram-LC Unknown 7e+07 cells Other

Indications

alcoholic liver cirrhosis